Medically reviewed by Doru Paul, MD Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

4,5 “Multiple myeloma disproportionately impacts African ... 3 FDA’s analysis in Blood, the official journal of the American Society of Hematology (ASH), appeared on December 7, 2017, timed ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has previously been refractory to. Read more.